In a report published Monday, Bank of America analyst Steve Byrne initiated coverage on MacroGenics MGNX with a Neutral rating and $30.00 price target.
In the report, Bank of America noted, “We are initiating coverage of MacroGenics (MGNX), a clinical stage oncology focused biopharmaceutical company with a $30 PO and Neutral rating. We believe MGNX' three immunotherapy platforms have meaningful potential, based primarily on pre-clinical data. The lead asset margetuximab is a modified version of Herceptin with increased binding affinity to cell-killing macrophages. MGA271 is another tumor targeting antibody that could block cancer-caused T-cell inhibition (same receptor family as PD1). MGNX also has a bi-functional antibody technology called DART, which could offer significant advantages vs. conventional antibodies (e.g. simultaneous binding to tumor and T-cells). Our DCF-derived PO of $30 is driven primarily by margetuximab. We could see upside post data read-outs in 2014.”
MacroGenics closed on Friday at $27.32.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in